Clinical trial

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555

Study summary

ClinicalTrials.gov

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-12-16

PhasePHASE3

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

OsimertinibDRUG · verified · RxNorm: osimertinib

CisplatinDRUG · verified · RxNorm: cisplatin

CarboplatinDRUG · verified · RxNorm: carboplatin

PlaceboDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

TaipeiTaiwan4 GuangzhouChina4 LimaPeru4 SeoulSouth Korea3 BeijingChina3 ShanghaiChina3 São PauloBrazil3 AnkaraTurkey (Türkiye)3 Saint PetersburgRussia2 IstanbulTurkey (Türkiye)2 TaichungTaiwan2 BangkokThailand2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04351555 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.